Australia Endoscopy Devices Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

Market Overview

The Australia endoscopy devices market is expanding because screening, ageing and technology are pulling in the same direction. Colonoscopy still anchors demand, yet urology, bronchoscopy and ear, nose and throat procedures are adopting single-use scopes and software-assisted imaging faster than the established reusable base.

Three forces are shaping the market: a national bowel screening program that now invites people from age 45, with a positivity rate of 5.8% in the latest data; long follow-up waits, with a national median of 62 days for diagnostic assessment; and regulatory attention on software, as the Therapeutic Goods Administration made medical device software a 2026 compliance priority.

In February 2026 Medtronic received a CE Mark for its ColonPRO polyp sizing software, and in April 2026 Boston Scientific reported endoscopy sales of USD 736 million for the quarter. In August 2026 Pentax Medical extended its artificial intelligence colonoscopy partnership to Asia-Pacific.

Key Market Trends and Insights

• Screening participation gap: Participation in the National Bowel Cancer Screening Program stood at 42% in data reported in June 2026, so more than half of invited Australians still skip the free home test.
• Younger cohort uptake: People aged 45 to 49 requested 236,421 kits, and 56.2% were returned, with 4.7% of returned kits positive and sent for further assessment, as reported in June 2026.
• Follow-up capacity strain: RACGP newsGP reported in August 2025 a national median wait of 62 days for colonoscopy after a positive test, with only 13.9% of patients seen within 30 days.
• Single-use momentum: Ambu reported on 4 February 2026 that Endoscopy Solutions grew 14.4% organically in the quarter, with its urology, ENT and gastroenterology scopes up 21.0%.

Australia Endoscopy Devices Market Size and Forecast

The market is moving from purely reusable video scopes towards a mix of reusable platforms, single-use scopes for urology and airways, and software that helps endoscopists find and size polyps. Reusable endoscopes lead in value because hospitals keep large installed fleets, while single-use endoscopes advance fastest as infection control and reprocessing costs weigh on buyers. Gastrointestinal procedures lead by volume, and urology grows quickest. Private hospitals carry the largest share of procedures, and day surgery centres expand fastest as lists move out of public wards. New South Wales remains the largest region, and Queensland grows quickest on population inflow and early software adoption. Screening policy and regulatory clarity point to a durable shift in product mix.

Key Takeaways: Australia Endoscopy Devices Market

Screening Policy Keeps Procedure Volumes Rising

Revenue is on course to expand by about 88% across the decade, from USD 520.00 million in 2025 to USD 976.11 million in 2035 at a 6.5% CAGR. Free home test kits for ages 45 to 49 and a 5.8% positivity rate feed a pipeline of colonoscopies that public and private providers must absorb.

Single-Use and Urology Lead Growth

Reusable Endoscopes hold the largest share, but Single-Use Endoscopes grow at an estimated 9.8% CAGR and Urology at an estimated 7.6% CAGR through 2035. Ambu reported urology, ENT and gastroenterology scope growth of 21.0% in February 2026, and Boston Scientific reported endoscopy sales of USD 736 million in April 2026.

Software Regulation Shapes Artificial Intelligence Adoption

The Therapeutic Goods Administration treats artificial intelligence software with a clinical purpose as a regulated medical device, and in 2026 it named software one of its priority compliance areas.

• Mater in Queensland reported in May 2026 that polyp detection software has run for over a year
• Medtronic added polyp sizing at 85.8% accuracy in February 2026
• Pentax Medical took its detection partnership to Asia-Pacific in August 2026

Australia Endoscopy Devices Market Report Summary

Key Insight

Screening policy, ageing and software-assisted imaging lift procedure volumes and supplier investment, while single-use scopes gain share. The largest state leads, and the fastest growth sits in the north.

Key Trends in the Australia Endoscopy Devices Market

The Australia endoscopy devices market is being reshaped by software regulation, widening bowel screening, hospital adoption of polyp detection and pressure on colonoscopy waiting times.

July 2026 - Regulator Clarifies When Artificial Intelligence Software Counts as a Medical Device

• Clayton Utz reported on 24 July 2026 that the Therapeutic Goods Administration set out when artificial intelligence software is regulated under existing device rules.
• Software with a diagnostic or treatment purpose must be on the ARTG, and the regulator listed software among 12 compliance priorities for 2026 and 2027.
• Polyp detection vendors need clear intended-purpose claims and clinical evidence.

June 2026 - Bowel Screening Data Show 42% Participation and Strong Uptake From Ages 45 to 49

• The West Australian reported on 17 June 2026 that almost 2.7 million of 6.4 million invited people took part, with 73,724 positive results.
• Some 85% of positive participants had a follow-up assessment, and about 1 in 29 had confirmed or suspected bowel cancer.
• Each positive result needs a colonoscopy, so rising screening feeds demand for scopes, processors and accessories.

May 2026 - Mater in Queensland Reports a Year of Artificial Intelligence Polyp Detection

• Mater said on 27 May 2026 that software added to its colonoscopy system highlights polyps by drawing a box around them in real time.
• Dr Sylvia Vigh described the software as highly accurate and said it has been in use for more than a year.
• Private hospitals that adopt detection tools can set a benchmark public peers may follow.

August 2025 - Colonoscopy Wait Times Stay Well Beyond the Recommended 30 Days

• RACGP newsGP reported on 4 August 2025 that no state or territory met the 30-day timeline, with a national median of 62 days.
• The Northern Territory recorded the longest median at 78 days, and Victoria the shortest at 54 days.
• Long waits push procedures towards private day surgery and favour devices that speed turnaround.

Key Insight

Software regulation, wider bowel screening and hospital adoption of polyp detection are the main structural forces, while colonoscopy capacity and waiting times remain the main constraint on volume.

Recent Market Developments in the Australia Endoscopy Devices Market

Recent developments, presented from the most recent, show artificial intelligence partnerships, quarterly endoscopy sales, new polyp sizing software and a next-generation imaging platform.

August 2026 - Pentax Medical Extends MAGENTIQ-COLO Partnership to Japan and Asia-Pacific

• RTTNews reported on 26 August 2026 that Pentax Medical will market and support the platform across EMEA, Japan, Asia-Pacific and Latin America.
• MAGENTIQ-COLO combines polyp detection, diagnosis and quality measures, and is integrated with the INSPIRA and IMAGINA processors.
• A published trial showed a 26% relative rise in adenoma detection, which supports adoption by Australian gastroenterology units.

April 2026 - Boston Scientific Reports Endoscopy Sales of USD 736 Million for the Quarter

• Boston Scientific announced its first quarter results on 22 April 2026, showing endoscopy sales growth of 9.4% on a reported basis.
• The company also reported FDA clearance of its LithoVue Elite single-use flexible ureteroscope system in the quarter.
• Single-use urology scopes are gaining ground, which supports faster growth for urology applications in Australian hospitals.

February 2026 - Medtronic Receives CE Mark for ColonPRO and a New GI Genius Module

• Medtronic announced on 23 February 2026 a CE Mark for ColonPRO, fourth-generation software that estimates polyp size in real time.
• The sizing module reached 85.8% accuracy in the METER study, against under 60% for routine visual estimates.
• The redesigned module runs several artificial intelligence applications on one platform, which suits hospitals consolidating vendors.

October 2025 - Fujifilm Launches ELUXEO 8000 Endoscopic Imaging System

• Fujifilm Healthcare Americas announced the system on 22 October 2025 as a single-unit 4K processor and light source.
• It adds Amber-Red Color Imaging to Linked Color Imaging and Blue Light Imaging, and works with the 500 to 800 series scopes.
• Backward compatibility lets hospitals upgrade processors without replacing scope fleets.

Key Insight

Artificial intelligence partnerships, polyp sizing software and new imaging platforms show suppliers competing on software and single-use ranges as hospitals refresh equipment through the forecast period.

Australia Endoscopy Devices Industry Segmentation

The Expert Market Research’s report on the Australia Endoscopy Devices Market offers a detailed analysis of the market based on the following segments.

Market Breakup by Product Type

• Reusable Endoscopes
• Single-Use Endoscopes
• Capsule Endoscopes
• Visualisation Systems and Accessories
• Others

Reusable Endoscopes lead on value, in our estimate, because hospitals maintain large fleets of video colonoscopes, gastroscopes and cystoscopes. Single-Use Endoscopes grow fastest at an estimated 9.8% CAGR through 2035, with Ambu reporting 14.4% organic growth in Endoscopy Solutions on 4 February 2026 and Boston Scientific clearing a single-use ureteroscope in the first quarter of 2026. Capsule Endoscopes serve small bowel and screening-follow-up niches and grow steadily. Visualisation Systems and Accessories cover processors, light sources, software, forceps and snares, and benefit from Fujifilm's ELUXEO 8000 launch of October 2025 and Medtronic's ColonPRO software of February 2026.

Market Breakup by Application

• Gastrointestinal Endoscopy
• Urology
• Pulmonology
• Others

Gastrointestinal Endoscopy leads in value, in our estimate, because screening follow-up drives colonoscopy and Mater in Queensland said in May 2026 that it has used polyp detection for over a year. Urology grows fastest at an estimated 7.6% CAGR through 2035, supported by single-use ureteroscopes and Boston Scientific's April 2026 results. Pulmonology grows steadily on bronchoscopy for lung nodule work and airway infection control. Others include ear, nose and throat, gynaecology and orthopaedic procedures, and the Therapeutic Goods Administration's July 2026 software guidance affects imaging tools used across all applications.

Market Breakup by End User

• Public Hospitals
• Private Hospitals
• Day Surgery and Endoscopy Centres
• Specialist Clinics
• Others

Private Hospitals lead, in our estimate, because most elective colonoscopies and gastroscopies are performed in the private system, and Mater in Queensland reported in May 2026 a year of software-assisted detection. Public Hospitals carry diagnostic follow-up for screening, where a national median wait of 62 days was reported in August 2025. Day Surgery and Endoscopy Centres grow fastest at an estimated 8.2% CAGR through 2035 as lists move out of wards. Specialist Clinics cover urology, ear, nose and throat and respiratory rooms that use compact and single-use scopes.

Market Breakup by Region

• New South Wales
• Victoria
• Queensland
• Western Australia
• Others

New South Wales dominates, in our estimate, as the most populous state with the largest hospital base, and it grows at an estimated 6.2% CAGR through 2035 from a large, mature base. Queensland is the fastest-growing region at an estimated 7.2%, on population inflow and early adoption such as Mater's polyp detection software reported in May 2026. Victoria grows at 6.4%, with the shortest national median colonoscopy wait of 54 days in August 2025. Western Australia grows at 6.9% on resource-region demand. Others, covering the remaining states and territories where the Northern Territory had the longest wait of 78 days, grow at 6.1%.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Competitive Landscape in the Australia Endoscopy Devices Market

Competition combines Japanese imaging specialists, global medical technology groups, single-use pioneers and local software developers. Entry barriers include installed scope fleets, Therapeutic Goods Administration device inclusion, reprocessing compatibility, clinical evidence for software, and service networks spanning metropolitan and regional hospitals.

Olympus

Olympus, headquartered in Tokyo, Japan, supplies gastrointestinal, urology and respiratory endoscopes, video processors, and reprocessing equipment in Australia through Olympus Australia. In June 2025 the US Food and Drug Administration placed import alerts on 58 Olympus models, including ureterorenoscopes, bronchoscopes and laparoscopes, over quality system concerns at a Japanese site. Olympus said it was working to complete its regulatory commitments, which keeps service quality and recall management under close scrutiny.

Fujifilm

Fujifilm, headquartered in Tokyo, Japan, sells flexible gastrointestinal endoscopes, processors and its CAD EYE artificial intelligence polyp detection tool through its healthcare business. On 22 October 2025 Fujifilm Healthcare Americas launched the ELUXEO 8000 imaging system, a 4K processor and light source with a new Amber-Red Color Imaging mode, compatible with its 500 to 800 series scopes. Backward compatibility suits Australian hospitals upgrading imaging while keeping existing scope fleets.

Medtronic

Medtronic, headquartered in Galway, Ireland with operations in Minneapolis, supplies the GI Genius intelligent endoscopy module, the first artificial intelligence system cleared for polyp detection, plus accessories and capsule products. On 23 February 2026 it announced a CE Mark for a redesigned module and ColonPRO software, which estimates polyp size in real time with 85.8% accuracy in the METER study.

Boston Scientific

Boston Scientific, headquartered in Marlborough, Massachusetts, sells single-use endoscopes, biliary and urology scopes, stents, clips and hemostasis accessories used in gastroenterology and urology suites. Its first quarter 2026 results, announced on 22 April 2026, showed endoscopy sales of USD 736 million, up 9.4% on a reported basis, and FDA clearance of the LithoVue Elite single-use flexible ureteroscope. That product direction fits the faster growth in urology applications in Australian hospitals.

Other players operating in the Australia endoscopy devices market include Pentax Medical, Ambu, Karl Storz, Stryker, and Optiscan Imaging, alongside regional distributors, reprocessing and service specialists, software developers and accessory suppliers serving public hospitals, private hospitals, day surgery centres and specialist clinics across Australia.

Key Insight

Competition rests on installed scope fleets, regulatory inclusion, clinical evidence for software and service reach rather than price alone, while single-use entrants keep widening choice for buyers.